Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis

Autoimmunity Reviews

Volumn 17, Issue 10, 2018, Pages 1011-1021

  Dufrost, Virginie ^a   Risse, Jessie ^a   Reshetnyak, Tatiana ^b   Satybaldyeva, Maria ^b   Du, Yao ^c   Yan, Xin Xin ^c   Salta, Stella ^d,e   Gerotziafas, Grigorios ^d,e   Jing, Zhi Cheng ^c   Elalamy, Ismaël ^d,e   Wahl, Denis ^a   Zuily, Stéphane ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^c FUWAI HOSPITAL   (China)

^d INSERM   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Arterial thrombosis; Direct oral anticoagulants; Recurrent thrombosis; Triple positivity

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; PHOSPHOLIPID ANTIBODY; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; DISEASE PREDISPOSITION; FOLLOW UP; HUMAN; MEDICAL HISTORY; META ANALYSIS; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SYSTEMATIC REVIEW; THROMBOSIS; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; PATHOPHYSIOLOGY; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CROSS-SECTIONAL STUDIES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; THROMBOSIS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 85051722537     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2018.04.009     Document Type: Review

References (78)

1. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R. et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH 4 (2006), 295–306, 10.1111/j.1538-7836.2006.01753.x.
2. Cervera, R., Piette, J.-C., Font, J., Khamashta, M.A., Shoenfeld, Y., Camps, M.T. et al., Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002), 1019–1027.
3. Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F. et al., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118 (2011), 4714–4718, 10.1182/blood-2011-03-340232.
4. Erkan, D., Aguiar, C.L., Andrade, D., Cohen, H., Cuadrado, M.J., Danowski, A. et al., 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 13 (2014), 685–696, 10.1016/j.autrev.2014.01.053.
5. Schulman, S., Kearon, C., Kakkar, A.K., Mismetti, P., Schellong, S., Eriksson, H. et al., Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361 (2009), 2342–2352, 10.1056/NEJMoa0906598.
6. Einstein Investigators, Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H. et al., Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510, 10.1056/NEJMoa1007903.
7. Agnelli, G., Buller, H.R., Cohen, A., Curto, M., Gallus, A.S., Johnson, M. et al., Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808, 10.1056/NEJMoa1302507.
8. Investigators, Hokusai-VTE, Büller, H.R., Décousus, H., Grosso, M.A., Mercuri, M., Middeldorp, S. et al., Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369 (2013), 1406–1415, 10.1056/NEJMoa1306638.
9. Dufrost, V., Risse, J., Wahl, D., Zuily, S., Comment on: failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome: reply. Rheumatol Oxf Engl 57 (2018), 939–940, 10.1093/rheumatology/kex464.
10. Dufrost, V., Risse, J., Wahl, D., Zuily, S., Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A Systematic Review of the Literature: Response to Comment. Curr Rheumatol Rep, 19, 2017, 52, 10.1007/s11926-017-0676-2.
11. Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M. et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 4, 2015, 1, 10.1186/2046-4053-4-1.
12. Cohen, H., Hunt, B.J., Efthymiou, M., Arachchillage, D.R.J., Mackie, I.J., Clawson, S. et al., Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 3 (2016), e426–e436, 10.1016/S2352-3026(16)30079-5.
13. Goldhaber, S.Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M. et al., Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER® RE-COVER™ II, and RE-MEDY™. Vasc Med Lond Engl 21 (2016), 506–514, 10.1177/1358863X16668588.
14. Schaefer, J.K., McBane, R.D., Black, D.F., Williams, L.N., Moder, K.G., Wysokinski, W.E., Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 112 (2014), 947–950, 10.1160/TH14-03-0272.
15. Win, K., Rodgers, G.M., New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol, 89, 2014, 1017, 10.1002/ajh.23797.
16. Noel, N., Dutasta, F., Costedoat-Chalumeau, N., Bienvenu, B., Mariette, X., Geffray, L. et al., Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev 14 (2015), 680–685, 10.1016/j.autrev.2015.03.007.
17. Sciascia, S., Savino, S., Breen, K., Hunt, B.J., Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis Int J Haemost Thromb 26 (2015), 476–477, 10.1097/MBC.0000000000000247.
18. Signorelli, F., Nogueira, F., Domingues, V., Mariz, H.A., Levy, R.A., Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol 35 (2016), 801–805, 10.1007/s10067-015-3030-y.
19. Betancur, J.F., Bonilla-Abadía, F., Hormaza, A.A., Jaramillo, F.J., Cañas, C.A., Tobón, G.J., Direct oral anticoagulants in antiphospholipid syndrome: a real life case series. Lupus 25 (2016), 658–662, 10.1177/0961203315624555.
20. Dufrost, V., Risse, J., Kirchner, S., Zuily, S., Wahl, D., Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome. Rheumatol Oxf Engl 56 (2017), 1433–1434, 10.1093/rheumatology/kex086.
21. Haładyj, E., Olesińska, M., Rivaroxaban - a safe therapeutic option in patients with antiphospholipid syndrome? Our experience in 23 cases. Reumatologia 54 (2016), 146–149, 10.5114/reum.2016.61217.
22. Malec, K., Góralczyk, T., Undas, A., The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. Thromb Res 152 (2017), 93–97, 10.1016/j.thromres.2016.12.009.
23. Kunk, P.R., Brown, J., McShane, M., Palkimas, S., Gail, Macik B., Direct oral anticoagulants in hypercoagulable states. J Thromb Thrombolysis 43 (2017), 79–85, 10.1007/s11239-016-1420-x.
24. Mateos Rodríguez, J.J., Bellido, D., Castro, D., Portillo Sánchez, J., Vanegas, R., Núñez, García A., After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2 cases. Reumatol Clin, 2017, 10.1016/j.reuma.2017.04.010.
25. Resseguier, A.S., Pereira, B., Rieu, V., Le Guenno, G., Grobost, V., Ruivard, M., Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?. Lupus 26 (2017), 1297–1303, 10.1177/0961203317701841.
26. Scanvion, Q., Morell-Dubois, S., Yelnik, C.M., Bene, J., Gautier, S., Lambert, M., Comment on: Failure of rivaroxaban to prevent thrombosis in four patients with anti-phospholipid syndrome. Rheumatol Oxf Engl 57 (2018), 938–939, 10.1093/rheumatology/kex463.
27. Martinelli, I., Abbattista, M., Bucciarelli, P., Tripodi, A., Artoni, A., Gianniello, F. et al., Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica, 2018, 10.3324/haematol.2017.185132.
28. Bachmeyer, C., Elalamy, I., Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome. Clin Exp Dermatol 39 (2014), 840–841, 10.1111/ced.12378.
29. Guntz, J., Layios, N., Damas, P., Catastrophic antiphospholipid syndrome: case reports and review of the literature. Acta Anaesthesiol Belg 65 (2014), 87–94.
30. Isshiki, T., Sugino, K., Gocho, K., Furuya, K., Shimizu, H., Sekiya, M. et al., Primary antiphospholipid syndrome associated with diffuse alveolar hemorrhage and pulmonary thromboembolism. Intern Med Tokyo Jpn 54 (2015), 2029–2033, 10.2169/internalmedicine.54.4058.
31. Joalland, F., de Boysson, H., Darnige, L., Johnson, A., Jeanjean, C., Cheze, S. et al., Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne 35 (2014), 752–756, 10.1016/j.revmed.2014.04.012.
32. Delgado, M.G., Rodríguez, S., García, R., Sánchez, P., Sáiz, A., Calleja, S., Antiphospholipid syndrome of late onset: A difficult diagnosis of a recurrent embolic stroke. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 24 (2015), e209–e211, 10.1016/j.jstrokecerebrovasdis.2015.04.016.
33. Reshetnyak, T.M., Seredavkina, N.V., Satybaldyeva, M.A., Nasonov, E.L., Reshetnyak, V.I., Liver transplantation in a patient with primary antiphospholipid syndrome and Budd-Chiari syndrome. World J Hepatol 7 (2015), 2229–2236, 10.4254/wjh.v7.i19.2229.
34. Sugie, M., Iizuka, N., Shimizu, Y., Ichikawa, H., Cerebral venous thromboembolism in antiphospholipid syndrome successfully treated with the combined use of an anti-Xa inhibitor and corticosteroid. Intern Med Tokyo Jpn 54 (2015), 3051–3056, 10.2169/internalmedicine.54.5045.
35. Vergallo, R., Aguirre, A.D., Abtahian, F., Minami, Y., Soeda, T., Chatzizisis, Y.S. et al., Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome. Thromb Haemost 115 (2016), 237–239, 10.1160/TH15-05-0412.
36. Comuth, W., Christiansen, J.J., Bloch-Münster, A.-M., Husted, S., Bilateral adrenal gland hemorrhage in a patient treated with rivaroxaban. Blood Coagul Fibrinolysis Int J Haemost Thromb 28 (2017), 102–104, 10.1097/MBC.0000000000000541.
37. Dulíček, P., Antifosfolipidový syndrom a trombóza. Klin Farmakol Farm, 42–42, 2016, 43.
38. Keenan, J.B., Janardhanan, R., Larsen, B.T., Khalpey, Z., Aortic valve replacement for Libman-Sacks endocarditis. BMJ Case Rep, 2016, 2016, 10.1136/bcr-2016-215914.
39. Rokos, J., Heger, M., Stöllberger, C., Finsterer, J., Laufer, G., Wiedemann, D., Bipolar disorder, ischemic stroke, mitral valve vegetation and recurrent venous thrombosis due to antiphospholipid syndrome despite rivaroxaban. Int J Cardiol 221 (2016), 383–384, 10.1016/j.ijcard.2016.06.123.
40. Sukniam, K.B., Proia, A.D., Glower, D.D., Catastrophic antiphospholipid syndrome after cardiac surgery. J Card Surg 31 (2016), 584–586, 10.1111/jocs.12811.
41. Bauersachs, R., Koitabashi, N., Overview of current evidence on the impact of the initial high dose of the direct factor Xa inhibitor rivaroxaban on Thrombus resolution in the treatment of venous thromboembolism. Int Heart J 58 (2017), 6–15, 10.1536/ihj.16-617.
42. Crowley, M.P., Cuadrado, M.J., Hunt, B.J., Catastrophic antiphospholipid syndrome on switching from warfarin to rivaroxaban. Thromb Res 153 (2017), 37–39, 10.1016/j.thromres.2017.03.006.
43. Deng, S., Shen, J., Ni, J., Gong, Y., Zhu, H., Cutaneous gangrene of the arms and legs after cardiopulmonary resuscitation: A rare presentation of catastrophic antiphospholipid syndrome. Am J Emerg Med, 35, 2017, 191.e3–191.e5, 10.1016/j.ajem.2016.06.086.
44. Hinojosa, C.A., Lizola, R., Laparra-Escareno, H., Anaya-Ayala, J.E., Endovascular recanalisation of a chronic occlusion of the retrohepatic IVC associated to a filter in a patient with antiphospholipid syndrome. BMJ Case Rep, 2017, 2017, 10.1136/bcr-2016-218697.
45. Hsu, Y.-W., Juan, C.-J., Lee, J.-T., Lin, Y.-K., Lai, C.-H., Yang, F.-C., Anti-N-methyl-D-aspartate-receptor encephalitis complicated with antiphospholipid syndrome and cerebral venous thrombosis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis 23 (2017), 294–295, 10.1097/RHU.0000000000000577.
46. Joshi, A., Hong, J., Siva, C., Recurrent thrombosis in patients with antiphospholipid syndrome receiving newer oral anticoagulants: a case report and review of literature. Clin Med Res 15 (2017), 41–44, 10.3121/cmr.2017.1349.
47. Kazzaz, N.M., Wilson, A.M., Kado, R., Barnes, G.D., Knight, J.S., A 37-year-old man with primary antiphospholipid syndrome presenting with respiratory distress and worsening toe ischemia. Arthritis Care Res 69 (2017), 1253–1259, 10.1002/acr.23168.
48. Robinson, E.A., Khalpey, Z.I., Janardhanan, R., A 24-year-old male with a painful and cold lower extremity. Heart Br Card Soc, 103, 2017, 765, 10.1136/heartjnl-2016-310872.
49. Satybaldyeva, M.A., Seredavkina, N.V., Kashnikova, L.N., Gorskikh, I.N., Nasonov, E.L., Reshetnyak, T.M., Direct thrombin inhibitors in patients with antiphospholipid syndrome. Eur Forum Antiphospholipid Antibodies, 2017.
50. Alvarez, C.S., Blackshear, J., Non-bacterial thrombotic endocarditis in a patient with antiphospholipid syndrome. Chest, 150, 2016, S92A.
51. Bryk, A., Undas, A., A Male patient with myocardial infarction as a first manifestation of antiphospholipid syndrome - Treatment with rivaroxaban. Kardiol Pol(Suppl. III), 2016, 19–22.
52. Patnaik, S., Fernandez, G., Aliling, J.-N., Rubin, A., Non-bacterial thrombotic endocarditis in a patient with primary antiphospholipid syndrome. J Am Coll Cardiol, 67(13), 2016, s1110.
53. O'Connor, A., Murphy, G., Cronin, S., Antiphospholipid syndrome associated crescendo stroke events treated with rituximab. Neurology, 86(S16), 2016, 4351.
54. Maden, M., Umit, E.G., Erdogan, S., Demir, A.M., Efficiency of direct oral anticoagulants on antiphospholipid antibody syndrome: A case report. Thromb Res, 141, 2016, S1:S27.
55. Bermejo, N., Sigüenza, R., Ibanez, F., Banas, M.H., Casas, I., Perez Leal, F.D.A. et al., Long-term anticoagulation with dabigatran in patients with severe lactose intolerance. Haematologica, 100, 2015, 802.
56. Webb, J., Hale, S., Guerrera, M., Maintenance therapeutic plasma exchange for refractory antiphospholipid antibody syndrome. J Clin Apheresis, 122, 2017.
57. Du, Y., Yan, X.-X., Sun, K., Lian, T.-Y., Jing, Z.-C., Oral rivaroxaban for the treatment of antiphospholipid syndrome. Res Pract Thromb Haemost, 1(Suppl.1), 2017, 939.
58. Gerotziafas, G.T., Lefkou, E., Gkalea, V., Spanoudaki, A., Ketatni, H., Evnorfiadis, I. et al., Rivaroxaban in long-term secondary prevention of VTE in patients with hereditary or acquired thrombophilia is as effective and safe as standard treatment with vitamin K antagonists. J Thromb Haemost(Suppl. 2), 2015, 964.
59. Unlu, O., Cohen, H., Cuadrado, M.J., Fortin, P.R., Ramires De Jesus, G., Gerosa, M. et al., Antiphospholipid syndrome alliance for clinical trials & international networking registry analysis: Direct oral anticoagulant use among antiphospholipid syndrome patients. Arthritis Rheumatol, 2016, 68.
60. Cervera, R., Serrano, R., Pons-Estel, G.J., Ceberio-Hualde, L., Shoenfeld, Y., de Ramón, E. et al., Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 74 (2015), 1011–1018, 10.1136/annrheumdis-2013-204838.
61. Pengo, V., Ruffatti, A., Legnani, C., Gresele, P., Barcellona, D., Erba, N. et al., Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost JTH 8 (2010), 237–242, 10.1111/j.1538-7836.2009.03674.x.
62. Van de Werf, F., Brueckmann, M., Connolly, S.J., Friedman, J., Granger, C.B., Härtter, S. et al., A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J, 163, 2012, 10.1016/j.ahj.2012.03.011 931–937.e1.
63. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A. et al., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151, 10.1056/NEJMoa0905561.
64. Pengo, V., Banzato, A., Bison, E., Zoppellaro, G., Padayattil Jose, S., Denas, G., Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 25 (2016), 301–306, 10.1177/0961203315611495.
65. Rivaroxaban in Thrombotic Antiphospholipid Syndrome - Full Text View - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02157272, 2018 (accessed April 25, 2018).
66. Crowther, M., Legnault, K.J., Garcia, David A., Tektonidou, M.G., Ugarte, A., Bruce, I.N. et al., Prevention and treatment of thrombotic antiphospholipid syndrome. Antiphospholipid Syndr. Curr. Res. Highlights Clin. Insights, 2017, 231 Erkan D, Lockshin MD. Springer New York.
67. Reilly, P.A., Lehr, T., Haertter, S., Connolly, S.J., Yusuf, S., Eikelboom, J.W. et al., The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63 (2014), 321–328, 10.1016/j.jacc.2013.07.104.
68. Ruff, C.T., Giugliano, R.P., Braunwald, E., Morrow, D.A., Murphy, S.A., Kuder, J.F. et al., Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet Lond Engl 385 (2015), 2288–2295, 10.1016/S0140-6736(14)61943-7.
69. Marcy, T.R., Truong, T., Rai, A., Comparing direct oral anticoagulants and warfarin for atrial fibrillation, venous thromboembolism, and mechanical heart valves. Consult Pharm J Am Soc Consult Pharm 30 (2015), 644–656, 10.4140/TCP.n.2015.644.
70. Frost, C., Song, Y., Barrett, Y.C., Wang, J., Pursley, J., Boyd, R.A. et al., A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol Adv Appl 6 (2014), 179–187, 10.2147/CPAA.S61131.
71. Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R.A. et al., Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76 (2013), 776–786, 10.1111/bcp.12106.
72. Schofield, J.R., Hassell, K., Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome. J Clin Pharm Ther 43 (2018), 104–106, 10.1111/jcpt.12582.
73. Cohen, H., Efthymiou, M., Isenberg, D., Use of direct oral anticoagulants in antiphospholipid syndrome. J Thromb Haemost JTH, 2018, 10.1111/jth.14017.
74. Cohen, H., Does a new blood thinning drug improve treatment for patients with lupus or thrombotic antiphospholipid syndrome at risk of stroke?. Arthritis Res. UK, 2018 https://www.arthritisresearchuk.org/research/grant-tracker-items/2018/does-a-new-blood-thinning-drug-improve-treatment-for-patients-with-lupus-or-thrombotic-antiphospholi.aspx.
75. Arachchillage, D.R.J., Mackie, I.J., Efthymiou, M., Chitolie, A., Hunt, B.J., Isenberg, D.A. et al., Rivaroxaban limits complement activation compared to warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Thromb Haemost JTH, 2016, 10.1111/jth.13475.
76. Arachchillage, D.R.J., Efthymiou, M., Mackie, I.J., Lawrie, A.S., Machin, S.J., Cohen, H., Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res 135 (2015), 388–393, 10.1016/j.thromres.2014.11.037.
77. Woller, S.C., Stevens, S.M., Kaplan, D.A., Branch, D.W., Aston, V.T., Wilson, E.L. et al., Apixaban for the secondary prevention of thrombosis among patients with antiphospholipid syndrome: study rationale and design (ASTRO-APS). Clin Appl Thromb Off J Int Acad Clin Appl Thromb 22 (2016), 239–247, 10.1177/1076029615615960.
78. Woller, S.C., Stevens, S.M., Kaplan, D.A., Rondina, T., Protocol modification of apixaban for the secondary prevention of thrombosis among patients with Antiphospholipid Syndrome Study. Clin Appl Thromb Off J Int Acad Clin Appl Thromb, 24, 2018, 192, 10.1177/1076029617729214.